PTU - Polskie Towarzystwo Urologiczne
list of articles:

Article published in Urologia Polska 1997/50/4.


Wiesław Sokołowski 1, Renata Jaskuła-Sztul 2, Ryszard Szpera 1, Krzysztof Szyfter 2
1 Oddział Urologii Z. Z. O. Z. Zarz±du Służby Zdrowia MSW w Poznaniu
Ordynator: dr n. med. Wiesław Sokołowski
2 Zakład Genetyki Człowieka PAN w Poznaniu
Kierownik: prof. dr hab. Jerzy Nowak


bladder cancer glutathione S-transferase genotyping


Objective. Genetic polymorphism was studied in respect to variability of
chemical carcinogens sensitivity.
Patients and methods. Using polymerase chain reaction (PCR), genotypes
of GST Ml and GST Tl were analysed in the group of 34 urinary bladder
cancer and in 180 controls.
Results. It was found that a proportions of the wild type and defeted
genotypes were comparable in patients and controls. However, in urinary
bladder cancer patients a defect in GST Tl was always accompanied by a
defect of GST Ml.
Conclusion. It seems reasonable, to claim that a coincidence of two defected
GST genes is responsible for an increased susceptibility to carcinogens,
particularly to those present in tobacco smoke. A correlation of malignacy
grading with genotypes appearance re±uires more studies.


  1. [1] Bell, D. A., Taylor, J. A., Paulson, D. F., Robertson, C. N., Mohler, J. L.,
  2. Lucier, G. W.: Genetic risk and carcinogen exposure: A common inherited defect of
  3. the carcinogen metabolism gene GST Ml that increases susceptibility to bladder
  4. cancer. J. Natl. Cancer Inst., 1993, 85,1159-1164.
  5. [2] Brockmóller, J., Kerb, R., Drakoulis, B., Roots, l.-.GSTMl anditszmńantsA
  6. and B as host factors of bladder cancer susceptibility: A case control study. Cancer
  7. Res., 1994, 54, 4103-4111.
  8. [3] Caparoso, N., Landi, M. T., Vineis, ?.:Relevance of metabolic poiymorphisms to
  9. human carcinogcnesis: Eualuation of epidemiologie evidence. Pharmacogenetics,
  10. 1991, 1, 4-19.
  11. [4] Guengerich, F. R, Shimada, T., Raney, K. D., Yun, Ch. H., Meyer, D. J.,
  12. Ketterer, B., Harris, T. M., Groopman, J. D., Kadlubar, F. ?.:Elucidation of
  13. catalytic specifities of human cytochrome P450 and GST enzymes and releimnce to
  14. molecular epidemiology. Environ. Health Perspectives, 1992, 98, 75-80.
  15. [5] Hirvonen, A., Nylund, L., Kociba, R, Husgafvel-Pursiainen, K., Vainio, H.:
  16. Modulation of urinary mutagenicity by genetically determined carcinogen metabo-
  17. lism in smokers. Carcinogenesis, 1994,15, 813-815.
  18. [6] Iscovitch, }., Castello, R., Esteve,)., Munoz, N., Colanzi, R., Coronel, A.
  19. Deamezola, I., Tassi, V., Arslan, A.: Tobacco, smoking, occupational exposurc
  20. and bladder cancer in Argentina. 1987,40, 734-740.
  21. [7] Jaskuła-Sztul, R., Hirvonen, A., Husgafvel-Pursiainen, K., Szmeja, Z.,
  22. Szyfter, W., Szyfter, K.: Glutathione S-transferase genotypes as modifiers of
  23. indwidual susceptibility to smoking related larynx cancer. W: Head & Neck cancer;
  24. adyances in basic research, pod red.: J. A. Wernera i in., Elsevier, Amsterdam
  25. 1996, 29-33.
  26. [8] Kadlubar, F. F.: DNA adducts of carcinogenic aromatic amines. W: DNA adducts:
  27. Identification and biological significance, pod red. K. Hemminkiego i in., Int. Agency
  28. Res. Cancer, Lyon 1994,199-216.
  29. [9] Kihara, M., Kihara, M., Noda, K.: Lung cancer risk of GSTMl null genotype is
  30. dependent on the extent oftobacco smoke exposure. Carcinogenesis, 1994,15,415-
  31. 417.
  32. [10] Lin, H. ]., Han, Ch. Y., Bernstein, D. A., Hsiao, W., Lin, B. K., Hardy, S.:
  33. Ethnic distribution of the GST Ml null genotype in 1473 individuals and applica-
  34. tion to bladder cancer susceptibility. Carcinogenesis, 1994,15,1077-1081.
  35. [U] Mikstacka, R.: Rola transferaz glutationowych w inaktywacji zwi±zków kancero-
  36. gennych. Post. Biochem., 1988,34,47-578.
  37. [12] Nakajima, T., Elovaara, E., Anttila, S., Hirvonen, A., Camus, A. M., Hayes,}. D.,
  38. Ketterer, B., Vainio, H.: Expression and polymorphism of GST in human lungs: Risk
  39. factors in smoking related lung cancer. Carcinogenesis, 1995,16, 707-711.
  40. [13] Roots, I., Drakoulis, N., Brockmoller, J.: Polymorphic enzymes and cancer risk:
  41. Concepts, methodology and data review. W: Pharmacogenetics of Drug Metabolism,
  42. pod red. W. Kałowa, Pergamon Press, Nowy Jork 1992,815-841.
  43. [14] Smith, G., Stanley, L. A., Sim, E., Strnage, R. C, Wolf, C. R.: Metabolic
  44. polymorphisms and cancer susceptibility. Cancer Survey, 1995, 25, 27-65.
  45. [15] Vainio, H., McGregor, D.: Approaches to the prediction of human cancer risk.
  46. Pharmacogenetics, 1992, 2, 337-343.
  47. [16] Vahakangas, K., Pelkonen, O.: Host variations in carcinogen metabolism and
  48. DNA repair. W: Genetic epidemiology of cancer, pod red. H. T. Lyncha i T. Hiray-
  49. amy, CRC Press, Boca Raton, 1989, 35-54.
  50. [17] Wynder, E. I., Goldsmith, R.: The epidemiology of bladder cancer: a second look.
  51. Cancer, 1977, 40, 1246-1268.